Kulandayan K. Subramanian

1.4k total citations
22 papers, 1.0k citations indexed

About

Kulandayan K. Subramanian is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Kulandayan K. Subramanian has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Kulandayan K. Subramanian's work include Neutrophil, Myeloperoxidase and Oxidative Mechanisms (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cell Adhesion Molecules Research (5 papers). Kulandayan K. Subramanian is often cited by papers focused on Neutrophil, Myeloperoxidase and Oxidative Mechanisms (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cell Adhesion Molecules Research (5 papers). Kulandayan K. Subramanian collaborates with scholars based in United States, Switzerland and Japan. Kulandayan K. Subramanian's co-authors include Hongbo R. Luo, Hidenori Hattori, Yonghui Jia, Hakryul Jo, Atul Narang, Jiro Sakai, Fabien Loison, Daocheng Zhu, Jian You and Subhanjan Mondal and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kulandayan K. Subramanian

22 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kulandayan K. Subramanian United States	16	490	414	185	167	141	22	1.0k
Chang-Duk Jun South Korea	12	320 0.7×	313 0.8×	104 0.6×	338 2.0×	103 0.7×	14	860
Roberto Campos‐González United States	16	622 1.3×	225 0.5×	332 1.8×	70 0.4×	120 0.9×	25	994
Neetu Gupta United States	13	412 0.8×	276 0.7×	158 0.9×	112 0.7×	67 0.5×	31	779
Arsenio Nueda Spain	18	622 1.3×	229 0.6×	100 0.5×	130 0.8×	109 0.8×	29	959
Norihiro Kotani Japan	22	842 1.7×	261 0.6×	380 2.1×	80 0.5×	128 0.9×	44	1.2k
Rihab R. Yassin United States	13	508 1.0×	280 0.7×	159 0.9×	140 0.8×	84 0.6×	17	833
Shunsuke Takasuga Japan	20	866 1.8×	317 0.8×	529 2.9×	112 0.7×	98 0.7×	37	1.5k
Karim Rezaul United States	15	1.1k 2.2×	354 0.9×	198 1.1×	49 0.3×	165 1.2×	22	1.5k
Amine Sadok United Kingdom	17	694 1.4×	195 0.5×	392 2.1×	101 0.6×	275 2.0×	17	1.3k
Mary Q. Stewart United States	7	567 1.2×	223 0.5×	276 1.5×	94 0.6×	145 1.0×	7	901

Countries citing papers authored by Kulandayan K. Subramanian

Since Specialization

Citations

This map shows the geographic impact of Kulandayan K. Subramanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kulandayan K. Subramanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kulandayan K. Subramanian more than expected).

Fields of papers citing papers by Kulandayan K. Subramanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kulandayan K. Subramanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kulandayan K. Subramanian. The network helps show where Kulandayan K. Subramanian may publish in the future.

Co-authorship network of co-authors of Kulandayan K. Subramanian

This figure shows the co-authorship network connecting the top 25 collaborators of Kulandayan K. Subramanian. A scholar is included among the top collaborators of Kulandayan K. Subramanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kulandayan K. Subramanian. Kulandayan K. Subramanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2024). A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2623–2623. 2 indexed citations

Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2023). Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors. Cancer Research. 83(8_Supplement). CT133–CT133. 1 indexed citations

Moser, Justin C., Mateusz Opyrchal, Mehmet Asım Bilen, et al.. (2023). 737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors. SHILAP Revista de lepidopterología. A830–A830. 2 indexed citations

Jankú, Filip, Sae‐Won Han, Toshihiko Doi, et al.. (2022). Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies. Cancer Immunology Research. 10(12). 1441–1461. 46 indexed citations

Fu, Siqing, Udai Banerji, Philippe L. Bédard, et al.. (2022). Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies. Cancer Research. 82(12_Supplement). CT503–CT503. 6 indexed citations

Jankú, Filip, Sae‐Won Han, Toshihiko Doi, et al.. (2020). 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. Regular and Young Investigator Award Abstracts. A230–A230. 12 indexed citations

Chaker, Adam, Mohamed H. Shamji, Moisés A. Calderón, et al.. (2015). Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial. Journal of Allergy and Clinical Immunology. 137(2). 452–461.e9. 45 indexed citations

Sakai, Jiro, Jingyu Li, Kulandayan K. Subramanian, et al.. (2012). Reactive Oxygen Species-Induced Actin Glutathionylation Controls Actin Dynamics in Neutrophils. Immunity. 37(6). 1037–1049. 169 indexed citations

Mondal, Subhanjan, Kulandayan K. Subramanian, Jiro Sakai, Besnik Bajrami, & Hongbo R. Luo. (2012). Phosphoinositide lipid phosphatase SHIP1 and PTEN coordinate to regulate cell migration and adhesion. Molecular Biology of the Cell. 23(7). 1219–1230. 51 indexed citations

10.

Hattori, Hidenori, Kulandayan K. Subramanian, Jiro Sakai, et al.. (2010). Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proceedings of the National Academy of Sciences. 107(8). 3546–3551. 132 indexed citations

11.

Simarro, Marı́a, Giorgio Giannattasio, Miguel Á. de la Fuente, et al.. (2010). Fas-Activated Serine/Threonine Phosphoprotein Promotes Immune-Mediated Pulmonary Inflammation. The Journal of Immunology. 184(9). 5325–5332. 18 indexed citations

12.

Hattori, Hidenori, Kulandayan K. Subramanian, Jiro Sakai, & Hongbo R. Luo. (2010). Reactive oxygen species as signaling molecules in neutrophil chemotaxis. Communicative & Integrative Biology. 3(3). 278–281. 36 indexed citations

13.

Kasorn, Anongnard, Pilar Alcaide, Yonghui Jia, et al.. (2009). Focal Adhesion Kinase Regulates Pathogen-Killing Capability and Life Span of Neutrophils via Mediating Both Adhesion-Dependent and -Independent Cellular Signals. The Journal of Immunology. 183(2). 1032–1043. 41 indexed citations

14.

Sarraj, Bara, Steffen Maßberg, Yitang Li, et al.. (2009). Myeloid-Specific Deletion of Tumor Suppressor PTEN Augments Neutrophil Transendothelial Migration during Inflammation. The Journal of Immunology. 182(11). 7190–7200. 32 indexed citations

15.

Jo, Hakryul, Yonghui Jia, Kulandayan K. Subramanian, Hidenori Hattori, & Hongbo R. Luo. (2008). Cancer Cell-Derived Clusterin Modulates the Phosphatidylinositol 3′-Kinase-Akt Pathway through Attenuation of Insulin-Like Growth Factor 1 during Serum Deprivation. Molecular and Cellular Biology. 28(13). 4285–4299. 52 indexed citations

16.

Jia, Yonghui, Kulandayan K. Subramanian, Christophé Erneux, et al.. (2007). Inositol 1,3,4,5-Tetrakisphosphate Negatively Regulates Phosphatidylinositol-3,4,5- Trisphosphate Signaling in Neutrophils. Immunity. 27(3). 453–467. 66 indexed citations

17.

Subramanian, Kulandayan K., Yonghui Jia, Daocheng Zhu, et al.. (2007). Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood. 109(9). 4028–4037. 97 indexed citations

18.

Zhu, Daocheng, Hidenori Hattori, Hakryul Jo, et al.. (2006). Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proceedings of the National Academy of Sciences. 103(40). 14836–14841. 71 indexed citations

19.

Subramanian, Kulandayan K. & Atul Narang. (2004). A mechanistic model for eukaryotic gradient sensing: Spontaneous and induced phosphoinositide polarization. Journal of Theoretical Biology. 231(1). 49–67. 46 indexed citations

20.

Narang, Atul, Kulandayan K. Subramanian, & Douglas A. Lauffenburger. (2001). A Mathematical Model for Chemoattractant Gradient Sensing Based on Receptor-Regulated Membrane Phospholipid Signaling Dynamics. Annals of Biomedical Engineering. 29(8). 677–691. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact